1. Executive Summary
1.1. Global Biological Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Biological Drugs Market Outlook, 2018 - 2031
3.1. Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Enbrel
3.1.1.2. Lantus
3.1.1.3. Neulasta
3.1.1.4. Avonex
3.1.1.5. NovoLog
3.1.1.6. Rebif
3.1.1.7. Humalog
3.1.1.8. Aranesp
3.1.1.9. Epogen
3.1.1.10. Levemir
3.1.1.11. Victoza
3.1.1.12. Betaseron
3.1.1.13. Neupogen
3.1.1.14. Eylea
3.2. Global Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Humira
3.2.1.2. Remicade
3.2.1.3. Rituxan
3.2.1.4. Avastin
3.2.1.5. Herceptin
3.2.1.6. Lucentis
3.3. Global Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Prenvar
3.3.1.2. Gardasil
3.3.1.3. Fluzone
3.3.1.4. Varivax
3.3.1.5. Cervarix
3.4. Global Biological Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Global Biological Drugs Market Outlook, 2018 - 2031
4.1. North America Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Enbrel
4.1.1.2. Lantus
4.1.1.3. Neulasta
4.1.1.4. Avonex
4.1.1.5. NovoLog
4.1.1.6. Rebif
4.1.1.7. Humalog
4.1.1.8. Aranesp
4.1.1.9. Epogen
4.1.1.10. Levemir
4.1.1.11. Victoza
4.1.1.12. Betaseron
4.1.1.13. Neupogen
4.1.1.14. Eylea
4.2. Global Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Humira
4.2.1.2. Remicade
4.2.1.3. Rituxan
4.2.1.4. Avastin
4.2.1.5. Herceptin
4.2.1.6. Lucentis
4.3. Global Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Prenvar
4.3.1.2. Gardasil
4.3.1.3. Fluzone
4.3.1.4. Varivax
4.3.1.5. Cervarix
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.2. Key Highlights
4.4.2.1. Enbrel
4.4.2.2. Lantus
4.4.2.3. Neulasta
4.4.2.4. Avonex
4.4.2.5. NovoLog
4.4.2.6. Rebif
4.4.2.7. Humalog
4.4.2.8. Aranesp
4.4.2.9. Epogen
4.4.2.10. Levemir
4.4.2.11. Victoza
4.4.2.12. Betaseron
4.4.2.13. Neupogen
4.4.2.14. Eylea
4.5. North America Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. Humira
4.5.1.2. Remicade
4.5.1.3. Rituxan
4.5.1.4. Avastin
4.5.1.5. Herceptin
4.5.1.6. Lucentis
4.6. North America Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
4.6.1. Key Highlights
4.6.1.1. Prenvar
4.6.1.2. Gardasil
4.6.1.3. Fluzone
4.6.1.4. Varivax
4.6.1.5. Cervarix
4.7. North America Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.7.1.1. Key Highlights
4.7.1.2. U.S. Global Biological Drugs Market by Therapeutic Protein, Value (US$Bn), 2018 - 2031
4.7.1.3. U.S. Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
4.7.1.4. U.S. Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
4.7.1.5. Canada Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
4.7.1.6. Canada Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
4.7.1.7. Canada Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
4.7.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Global Biological Drugs Market Outlook, 2018 - 2031
5.1. Europe Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Enbrel
5.1.1.2. Lantus
5.1.1.3. Neulasta
5.1.1.4. Avonex
5.1.1.5. NovoLog
5.1.1.6. Rebif
5.1.1.7. Humalog
5.1.1.8. Aranesp
5.1.1.9. Epogen
5.1.1.10. Levemir
5.1.1.11. Victoza
5.1.1.12. Betaseron
5.1.1.13. Neupogen
5.1.1.14. Eylea
5.2. Europe Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Humira
5.2.1.2. Remicade
5.2.1.3. Rituxan
5.2.1.4. Avastin
5.2.1.5. Herceptin
5.2.1.6. Lucentis
5.3. Europe Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Prenvar
5.3.1.2. Gardasil
5.3.1.3. Fluzone
5.3.1.4. Varivax
5.3.1.5. Cervarix
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Global Biological Drugs Market Outlook, 2018 - 2031
6.1. Asia Pacific Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Enbrel
6.1.1.2. Lantus
6.1.1.3. Neulasta
6.1.1.4. Avonex
6.1.1.5. NovoLog
6.1.1.6. Rebif
6.1.1.7. Humalog
6.1.1.8. Aranesp
6.1.1.9. Epogen
6.1.1.10. Levemir
6.1.1.11. Victoza
6.1.1.12. Betaseron
6.1.1.13. Neupogen
6.1.1.14. Eylea
6.2. Asia Pacific Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Humira
6.2.1.2. Remicade
6.2.1.3. Rituxan
6.2.1.4. Avastin
6.2.1.5. Herceptin
6.2.1.6. Lucentis
6.3. Asia Pacific Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Prenvar
6.3.1.2. Gardasil
6.3.1.3. Fluzone
6.3.1.4. Varivax
6.3.1.5. Cervarix
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Global Biological Drugs Market Outlook, 2018 - 2031
7.1. Latin America Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Enbrel
7.1.1.2. Lantus
7.1.1.3. Neulasta
7.1.1.4. Avonex
7.1.1.5. NovoLog
7.1.1.6. Rebif
7.1.1.7. Humalog
7.1.1.8. Aranesp
7.1.1.9. Epogen
7.1.1.10. Levemir
7.1.1.11. Victoza
7.1.1.12. Betaseron
7.1.1.13. Neupogen
7.1.1.14. Eylea
7.2. Latin America Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Humira
7.2.1.2. Remicade
7.2.1.3. Rituxan
7.2.1.4. Avastin
7.2.1.5. Herceptin
7.2.1.6. Lucentis
7.3. Latin America Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Prenvar
7.3.1.2. Gardasil
7.3.1.3. Fluzone
7.3.1.4. Varivax
7.3.1.5. Cervarix
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Global Biological Drugs Market Outlook, 2018 - 2031
8.1. Middle East & Africa Global Biological Drugs Market Outlook, by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Enbrel
8.1.1.2. Lantus
8.1.1.3. Neulasta
8.1.1.4. Avonex
8.1.1.5. NovoLog
8.1.1.6. Rebif
8.1.1.7. Humalog
8.1.1.8. Aranesp
8.1.1.9. Epogen
8.1.1.10. Levemir
8.1.1.11. Victoza
8.1.1.12. Betaseron
8.1.1.13. Neupogen
8.1.1.14. Eylea
8.2. Middle East & Africa Biological Drugs Market Outlook, by mAb, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Humira
8.2.1.2. Remicade
8.2.1.3. Rituxan
8.2.1.4. Avastin
8.2.1.5. Herceptin
8.2.1.6. Lucentis
8.3. Middle East & Africa Biological Drugs Market Outlook, by Vaccines, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Prenvar
8.3.1.2. Gardasil
8.3.1.3. Fluzone
8.3.1.4. Varivax
8.3.1.5. Cervarix
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Global Biological Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Global Biological Drugs Market by Therapeutic Protein, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Global Biological Drugs Market by mAb, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Global Biological Drugs Market by Vaccines, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Vaccines vs by mAb Heat map
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Abbott Laboratories
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Novartis AG
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Eli Lilly and Company
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. GlaxoSmithKline plc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Bristol-Myers Squibb Company
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Merck & Co., Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Amgen Inc.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Baxter International Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Biogen Idec
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1.Research Methodology
10.2.Report Assumptions
10.3.Acronyms and Abbreviations